RELMADA THERAPEUTICS, INC. (RLMD) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, RELMADA THERAPEUTICS, INC.'s filing signal turned positive.

Relmada Therapeutics is a clinical-stage biotechnology company strategically pivoting its development pipeline following a comprehensive review. The company has terminated its esmethadone (REL-1017) and psilocybin (REL-P11) programs to focus on two new candidates: NDV-01, a novel intravesical formulation of gemcitabine and docetaxel for non-muscle-invasive bladder cancer (NMIBC), and sepranolone, a neurosteroid targeting Prader-Willi syndrome, Tourette syndrome, and other neurological disorders. NDV-01 is currently in Phase 2 trials in Israel, with Phase 3 programs anticipated mid-2026, while sepranolone is slated for a Phase 2b study in Prader-Willi syndrome in mid-2026. Relmada has no commercial products and does not anticipate generating revenue in the foreseeable future.

The company has no commercial products and does not anticipate generating revenue in the foreseeable future. Future revenue will be dependent on the successful development, regulatory approval, and commercialization of its product candidates.